Priorities for research on neuromodulatory subcortical systems in Alzheimer's disease: Position paper from the NSS PIA of ISTAART

• DOI: 10.1002/alz.12937
• Publication Date: 2023-01-16T07:23:44Z
• Authors: Alexander J. Ehre...; Michael A. Kelberman; Kathy Y. Liu; Martin J. Dahl; David Weinshenker; Neus Falgàs; Shubir Dutt; Mara Mather; Mareike Ludwig; Matthew J. Betts; Joseph R. Winer; Stefan Teipel; Alexandra J. Weigand; Oxana Eschenko; Dorothea Hämmerer; Marina Leiman; Scott E. Counts; James M. Shine; Ian H. Robertson; Allan I. Levey; Elisa Lancini; Gowoon Son; Christoph Schneider; Maxime Van Egroo; Claudio Liguori; Qin Wang; Elena M. Vazey; Federico Rodrigue...; Lena Haag; Mark W. Bondi; Sven Vanneste; Whitney M. Freeze; Yeo‐Jin Yi; Mihovil Maldinov; Jennifer Gatchel; Abhijit Satpati; Claudio Babiloni; William S. Kremen; Robert Howard; Heidi I. L. Jacobs; Lea T. Grinberg
• Keywords: Degeneration (medical); Neuromodulation

Abstract The neuromodulatory subcortical system (NSS) nuclei are critical hubs for survival, hedonic tone, and homeostasis. Tau‐associated NSS degeneration occurs early in Alzheimer's disease (AD) pathogenesis, long before the emergence of pathognomonic memory dysfunction cortical lesions. Accumulating evidence supports role behavioral neuropsychiatric manifestations featured AD. Experimental studies even suggest that AD‐associated drives brain neuroinflammatory status contributes to progression, including exacerbation Given important pathophysiologic etiologic roles involve AD stages, there is an urgent need expand our understanding mechanisms underlying vulnerability more precisely detail clinical progression changes Here, Professional Interest Area International Society Advance Research Treatment highlights knowledge gaps about within provides recommendations priorities specific research, biomarker development, modeling, intervention. Highlights Neuromodulatory degenerate pathological stages. pathophysiology exacerbated by degeneration. symptoms dementia. Biomarkers integrity would be value‐creating dementia care. present strategic prospects disease‐modifying therapies.